Our in vitro outcomes advise that EAM-2201 needs to be examined in terms of potential in vivo pharmacokinetic drug–drug interactions because of time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 routines and competitive inhibition of UGT1A3 exercise. This is the preview of membership information, log in by using an institution https://popez949mcr3.blogripley.com/profile